Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Exclusion criteria

• ✕. Patients with vitiligo or alopecia
• ✕. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• ✕. Any chronic skin condition that does not require systemic therapy
• ✕. Patients without active disease in the last 5 years may be included but only after consultation with the PI
• ✕. Patients with celiac disease controlled by diet alone
• ✕. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the PI.
• ✕. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the PI.
• ✕. Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered (i.e., ≥ Grade 1 at baseline) from adverse events due to agents administered \> 4 weeks earlier (intraocular bevacizumab is acceptable).